Press release
Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)
CELEBRATION, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare
About this update from Zevra Therapeutics, Inc.
[{"type":"text","content":"CELEBRATION, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that it has become a Corporate Council member of the National Organization for Rare Disorders (NORD) and reiterated its commitment to the rare disease community by celebrating Rare Disease Day 2023. A rare disease is a condition that impacts fewer than 200,000 people in the United States, with over 7,000 known rare diseases nationally affecting nearly 1 in 10 people. NORD is dedicated to promoting research and access to therapies for the more than 300 million people worldwide with rare diseases, as well as raising awareness of this important community. As a company focused on advancing therapies for rare diseases, Zevra stands with NORD and the rare disease community today and every day. “Zevra’s dedication to the rare disease community is critical as we all work to bring much-needed therapies and relief to people affected by a rare condition without treatment options,\" said Peter L. Saltonstall, President and Chief Executive Officer of NORD. “We enthusiastically welcome Zevra as an important partner for our community and appreciate the symbolism of its new name inspired by the zebra – the international symbol of the rare disease community.\" On February 22, 2023, Zevra announced its new corporate name to embody the Company’s mission of innovating new therapies for people with rare conditions and the highest unmet needs. Zevra is Greek for zebra, the symbol of rare diseases. \"Rare Disease Day is both a reminder of the strides the rare disease community has made over the last four decades with the support of NORD's leadership, as well as a call to action to continue making meaningful progress in rare disease therapies,\" said Richard W. Pascoe, Chief Executive Officer of Zevra. “Zevra is proud to partner with NORD as we redouble our efforts to bring accessible treatments to patients with Niemann-Pick disease type C and idiopathic hypersomnia.\" Visit Zevra’s new corporate website at www.zevra.com to learn more. About ZevraZevra Therapeutics is a rare disease company melding science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. With unique, data-driven clinical, r...